Chardan Capital analyst Gbola Amusa maintained a Buy rating on uniQure (NASDAQ:QURE) N.V. on Monday, setting a price target of $100, which is approximately 172.48% above the present share price of $36.7.
Amusa expects uniQure N.V. to post earnings per share (EPS) of -$1.21 for the first quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in uniQure, with an average price target of $66.88.
The analysts price targets range from a high of $85 to a low of $52.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $1.79 million and a net profit of -$44.49 million. The company's market cap is $1.63 billion.
According to TipRanks.com, Chardan Capital analyst Gbola Amusa is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 35.6% and a 53.08% success rate.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.